Nurix Therapeutics News and Activities
Presence
Nurix Therapeutics develops targeted protein modulation medicines for cancer and immune disorders. It provides drug discovery, clinical development, and research partnerships for patients, healthcare providers, and pharmaceutical companies.
Nurix Therapeutics products and services overview:
- Cancer therapies
- Immune disorder drugs
- Protein degrader platforms
- Drug discovery services
- Research partnerships
Revenue: ~$95 million
Employees: 310
Headquarters: San Francisco, United States (USA)
Nurix Therapeutics is one of the...
Nurix Therapeutics is a company listed under the stock ticker NRIX (US).
Executives
View the org chart displaying its 35 main executives
Most searched biographies at Nurix Therapeutics
- Arthur Sands, Chief Executive Officer and Director
- Judith Reinsdorf, Director
- Edward Saltzman, Director
Popular executive movements at Nurix Therapeutics
- Roger Dansey has joined the company as Director (posted on November 10 2025).
Create your alert
to follow the executive moves at Nurix Therapeutics.
Biotechnology
Nurix Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Nurix Therapeutics
- Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress | Nurix Therapeutics, Inc.
- Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting | Nurix Therapeutics, Inc.
- Nurix Therapeutics to Participate in Upcoming Investor Conferences | Nurix Therapeutics, Inc.
- Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer | Nurix Therapeutics, Inc.
- Press Releases | Nurix Therapeutics, Inc.
- Press Releases | Nurix Therapeutics, Inc.
- Press Releases | Nurix Therapeutics, Inc.
- Nurix Therapeutics Announces $40 Million Registered Direct Offering | Nurix Therapeutics, Inc.
- Press Releases | Nurix Therapeutics, Inc.
- Nurix Therapeutics Announces $55 Million Registered Direct Offering | Nurix Therapeutics, Inc.
- View more press releases Close
Social media about Nurix Therapeutics
- Nurix Therapeutics on Wikipedia, Google News & Yahoo Finance
- Nurix Therapeutics on LinkedIn, X (Twitter) & YouTube
